Insulin human
- Generic Name
- Insulin human
- Brand Names
- Actraphane, Actrapid, Afrezza, Entuzity, Exubera, Humulin, Humulin N, Humulin R, Insulatard, Insuman, Myxredlin, Novolin, Novolin N, Novolin R, Protaphane, Mixtard
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 11061-68-0
- Unique Ingredient Identifier
- 1Y17CTI5SR
- Background
Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone prod...
- Indication
Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus
- Associated Therapies
- -
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 13
- Registration Number
- NCT01269606
Insulin Receptor Substrate 1 (IRS-1) Regulation in Insulin Resistance
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 14
- Registration Number
- NCT01240252
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Gulhane School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT01013402
- Locations
- 🇹🇷
Gulhane School of Medicine Department of Endocrinology and Metabolism, Ankara, Turkey
Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 4847
- Registration Number
- NCT00806936
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China
Follow-Up Study for Exubera
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7439
- Registration Number
- NCT00734591
- Locations
- 🇬🇧
Pfizer Investigational Site, Westbury, United Kingdom
Insulin and Sarcopenia in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2016-12-12
- Target Recruit Count
- 88
- Registration Number
- NCT00690534
- Locations
- 🇺🇸
Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas, United States
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT00676819
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Köln, Germany
Insulin Sensitivity of the Brain in Pathogenesis of Diabetes Mellitus Type 2
- Conditions
- Interventions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2008-03-19
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 42
- Registration Number
- NCT00638209
- Locations
- 🇩🇪
University Hospital Tuebingen, Internal Medicine IV, Tuebingen, Germany
🇩🇪University Hospital Tuebingen, Tuebingen, Germany
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes
- Conditions
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT00569400
- Locations
- 🇵ðŸ‡
Novo Nordisk Investigational Site, Marikina City, Philippines
Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes
- Conditions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00567775
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Glostrup, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.